4 completed, 3 terminated. 6 Phase 1, 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 4, Terminated 2 |
| Phase 2 | 3 | Terminated 2, Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Part 1: new trials by email Literature Review of Part 1 trials Research Report on Part 1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates Part 1, Part 2 - Drug Interaction | Phase 1 | Completed | Harmony Biosciences Management, Inc. | 29 | 2025-06-06 | 2026-02-09 |
| Phase 1/Phase 2a Study of AERO-007 Inhalation Solution, a Nebulized LABA/LAMA Combination for Maintenance Treatment of COPD AERO-001, AERO-002, AERO-007 - COPD | Phase 1 / Phase 2 | Completed | AeroRx Therapeutics Inc. | 24 | 2025-01-15 | 2025-08-01 |
| Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax - Leukemia, Myeloid | Phase 1 | Completed | Molecular Partners AG | 80 | 2022-12-29 | 2026-09-25 |
| A Study in Patients With Advanced Breast Cancer Part 1, Part 2, Part 3 - HER2-negative Breast Cancer, Advanced Breast Cancer | Phase 1 | Terminated | Sun Pharma Advanced Research Company Limited | 9 | 2022-05-20 | 2023-05-22 |
| Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL Part 1: Liposomal mitoxantrone hydrochloride and Pegaspargase, Part 2 (treatment-naïve patients): Liposomal mitoxantrone hydrochloride and Pegaspargase, Part 2 (relapsed or refractory patients): Liposomal mitoxantrone hydrochloride and Pegaspargase - Extranodal NK/T-cell Lymphoma, Nasal Type | Phase 1 / Phase 2 | Terminated | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 41 | 2020-09-15 | 2024-03-07 |
| Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo Part 1, Part 2 - Mild to Moderate COVID-19 | Phase 2 / Phase 3 | Terminated | Daewoong Pharmaceutical Co. LTD. | 432 | 2020-09-11 | 2022-06-15 |
| Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD) Part 1, Part 2 Group 1, Part 2 group 2 - Anaphylaxis | Phase 1 | Completed | Bausch & Lomb Incorporated | 43 | 2017-03-23 | 2019-06-21 |
Anaphylaxis (1) · Leukemia (1) · Lymphoma, Extranodal NK-T-Cell (1) · Pulmonary Disease, Chronic Obstructive (1) · Respiratory Aspiration (1)
AeroRx Therapeutics Inc. (1) · Bausch & Lomb Incorporated (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Daewoong Pharmaceutical Co. LTD. (1) · Harmony Biosciences Management, Inc. (1) · Molecular Partners AG (1) · Sun Pharma Advanced Research Company Limited (1)
Australia (1) · China (1) · France (1) · Germany (1) · India (1) · Lithuania (1) · Netherlands (1) · South Korea (1) · Switzerland (1) · United Kingdom (1) · United States (1)
Beate Klaus, MD (1) · Dave Singh, MD (1) · Kristen Bzdek, MD (1) · Ping Liu (1) · Thomas Polasek, MD, PhD (1)
2023 (1)